Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report released on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Evoke Pharma stock opened at $4.41 on Thursday. Evoke Pharma has a one year low of $3.54 and a one year high of $12.32. The business has a fifty day moving average of $4.49 and a two-hundred day moving average of $4.99. The company has a market cap of $6.55 million, a P/E ratio of -0.40 and a beta of 0.15.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.94) earnings per share for the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The firm had revenue of $2.65 million during the quarter.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.